Benzinga | Mar 16, 2021 04:13PM EDT

Exagen Q4 EPS $(0.27) Beats $(0.40) Estimate, Sales $12.70M Beat $10.76M Estimate

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.40) by 32.5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $12.70 million which beat the analyst consensus estimate of $10.76 million by 18.03 percent. This is a 24.34 percent increase over sales of $10.21 million the same period last year.